Masaryk University

Publication Records

česky | in English

Filter publications

    2009

    1. ZAORALOVÁ, Romana, Vladimíra VRANOVÁ, Jan SMETANA, Hana FILKOVÁ, Pavel NĚMEC, Roman HÁJEK and Petr KUGLÍK. Genomová profilace mnohočetného myelomu pomocí oligonukleotidové array-CGH. In 42. Cytogenetická konference, Brno. 2009.

    2007

    1. NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Vladimíra VRANOVÁ, Renata KUPSKÁ, Jana SMEJKALOVÁ, Alexandra OLTOVÁ, Petr KUGLÍK and Roman HÁJEK. Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy. In Hematologica/The Hematology Journal. Volume 92, supplement no.1. Pavia, Italy: Ferrata-Storti Foundation, 2007, p. 49-49. ISSN 0390-6078.
    2. HÁJEK, Roman, Petr KUGLÍK, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC and Jana SMEJKALOVÁ. Genetic lesions in multiple myeloma: prognostic and predictive significance in the era of the new drugs. In Blood Reviews, 2007; Vol. 21, Suppl.1. 2007. ISSN 0268-960X.
    3. NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Petr KUGLÍK, Hana FILKOVÁ, Romana ZAORALOVÁ, Vladimíra VRANOVÁ, Jana SMEJKALOVÁ, Petra VIDLÁKOVÁ, Alexandra OLTOVÁ and Roman HÁJEK. Newly Diagnosed Multiple Myeloma Patients with 1q21 Amplification Treated by Autologous Stem Cell Transplantation Have Shorter Progression-Free Survival Interval. In Blood 2007, Vol.110(11) Part 2. Washington DC, USA: American Society of Hematology (ASH), 2007, p. 263B-263B, 1 pp. ISSN 0006-4971.
    4. HÁJEK, Roman and Petr KUGLÍK. Prognostic and predictive significance of genetic lesions in multiple myeloma. In Acta Haematologica Polonica, 2007; Vol.38, suppl. 1. 2007. ISSN 0001-5814.
    5. NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Petr KUGLÍK, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ and Roman HÁJEK. Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by bortezomib (velcade). In Hematologica/The Hematology Journal. Volume 92, no. 6 supplement. Pavia, Italy: Ferrata-Storti Foundation, 2007, p. 165-165. ISSN 0390-6078.
    6. NĚMEC, Pavel, Petr KUGLÍK, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Jana SMEJKALOVÁ, Alexandra OLTOVÁ and Roman HÁJEK. Prognostic impact of 1q21 amplification for newly diagnosed and relapsed/refractory multiple myeloma patients enrolled in Brno, Czech Republic. In From cell sorting to plasma cell identification and detection chromosomal aberrations in multiple myeloma. Abstract and Application Manual. Brno, Czech Republic: Masaryk University, 2007, p. 9-11. ISBN 978-80-210-4417-3.
    7. NĚMEC, Pavel, Petr KUGLÍK, Vladimíra VRANOVÁ, Romana ZAORALOVÁ, Henrieta GREŠLIKOVÁ, Alexandra OLTOVÁ, Hana FILKOVÁ, Petra VIDLÁKOVÁ, Jana SMEJKALOVÁ and Roman HÁJEK. Prognostic impact of 1q21 amplification in patients with multiple myeloma treated by velcade, thalidomide and any conventional chemotherapy. In Blood Reviews. Volume 21, Supplement 1. Neuveden: Elsevier, 2007, p. 131-131. ISSN 0268-960X.
    8. HÁJEK, Roman, Romana ZAORALOVÁ, Luděk POUR, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Petr KUGLÍK, Alexandra OLTOVÁ, Zdeněk ADAM, Andrea KŘIVANOVÁ and Marta KREJČÍ. Prospective comparison of response rate and long-term results of Velcade and thalidomid based regimens. In Haematologica/The Hematology Journal, 2007; Vol.92(6) suppl.2. Pavia, Itálie: Ferrata-Storti Foundation, 2007, p. 210-210. ISSN 0390-6078.
Display details
Displayed: 8/6/2024 21:49